By Fineline Cube In May 2026, Hunan Zonsen PepLib Biotech Inc. successfully completed a Series C financing round of over RMB 300 million, with a post-money valuation approaching RMB 5 billion.
Financing Details
| Item | Detail |
|---|---|
| Company | Hunan Zonsen PepLib Biotech Inc. |
| Financing Round | Series C |
| Amount Raised | Over RMB 300 million (approximately USD 42 million) |
| Post-Money Valuation | Approaching RMB 5 billion |
| Completion Date | May 2026 |
Investor Consortium
- Co-Lead Investors: Lilly Asia Ventures and CDH Investments
- Continued Participation: Multiple renowned institutions
- New Strategic Shareholder: Hong Kong Investment Corporation Limited (“HKIC”) through its wholly-owned investment vehicle, OG Compressor (Hong Kong) Limited
- Strategic Value: HKIC brings long-term stable patient capital and global industrial ecosystem resources
Company Profile & Technology Platform
Since its inception, Zonsen PepLib has been deeply committed to the discovery and development of peptide-based new drugs, and has established a comprehensive technology system for peptide drug molecular discovery and preclinical development. The company has built significant strengths in cutting-edge fields including:
- Radionuclide Drug Conjugates (RDC)
- Peptide-Drug Conjugates (PDC)
- Peptide-Oligonucleotide Conjugates (POC)
The company has laid out a pipeline of over 50 innovative drug programs spanning multiple therapeutic areas.
Strategic Partnerships & Commercial Success
In early 2026, the company entered into global licensing and collaboration agreements with multinational corporations including Eli Lilly and Novartis for its peptide pipeline assets, securing:
- Upfront payments exceeding USD 50 million
- Potential additional milestone payments and royalties
Future Strategic Direction
Looking ahead, Zonsen PepLib will continue to deepen its strategic collaboration with HKIC to advance frontier technologies in peptide-based innovative drugs and accelerate the delivery of innovative products to the market.
Market Context & Competitive Positioning
- Global Peptide Therapeutics Market: Projected to exceed USD 56 billion by 2028
- Competitive Advantage: Proprietary peptide library technology and comprehensive discovery platform
- Strategic Positioning: Strong partnerships with global pharmaceutical leaders validate technology platform
- Commercial Potential: Diversified pipeline across multiple conjugate modalities (RDC, PDC, POC)
Company Statement
“This Series C financing represents a pivotal milestone for our organization,” said a company spokesperson. “The overwhelming support from our investors validates our innovative approach to peptide drug discovery and provides the necessary resources to advance our clinical programs and scale our operations globally.”
Forward‑Looking Statements
This brief contains forward-looking statements regarding financing, business development, and commercial expectations. Actual results may differ due to market dynamics, competitive pressures, partnership execution, and other risk factors.-Fineline Info & Tech